EGb 761 for mild cognitive impairment together with cerebrovascular disease
Tests EGb 761 in people with mild cognitive impairment and cerebrovascular disease.
Key facts
- Who runs it
- National Neuroscience Institute
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- EGb 761 in the Syndrome of MCI With Concomitant CVD
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 134 people, planned
- Started
- 26 Oct 2020
- Expected to end
- Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Tebonin Forte
- Record updated
- 17 November 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild cognitive impairment (mild memory and thinking problems) who also have disease of the brain's blood vessels.
- Age
- 45 to 85 years
- Sex
- All sexes
- Disease stage
- Mild cognitive impairment diagnosed by the Petersen criteria and Albert MS criteria, with a Global Clinical Dementia Rating Score of 0.5. Blood vessel disease of the brain means white matter changes (white matter hyperintensities) of Fazekas grade 2 or 3. These must be seen on an MRI scan done up to 12 months before joining, or a CT scan if MRI cannot be done.
Main reasons for not taking part
- Taking antidepressants, antipsychotics or benzodiazepines during the study
- Taking acetylcholinesterase inhibitors or NMDA antagonists (dementia drugs) during the study
- Any reason listed in the drug's product information why EGb 761 must not be used
- Not able to read and write, or not able to complete the memory and thinking tests
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria
- Patients who have a Global Clinical Dementia Rating Score of 0.5
- Patients aged 45 to 85 years at study entry
- Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators
- Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans
- Patients who provide written informed consent to participate in the study
Who cannot take part
- Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information/Summary of Product Characteristics (SmPC) should be observed
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 45 and 85 years old?
This trial is currently available in Singapore.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.
The 2 groups in the trial
- Tebonin ForteTreatment being tested
Treatment: 120mg, twice a day, 52 weeks
- ControlNo study treatment, for comparison
No Treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)
- Plain-language title
- EGb 761 for mild cognitive impairment together with cerebrovascular diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT04525144, who can take part
- Record updated
- 17 November 2022